COL8A1 and glioma: We provide a convincing case for targeting COL8A1 to enhance glioma therapy by thoroughly characterizing its prognostic value, validating its pro-tumorigenic functions in vitro, unraveling its complex role in forming an immunosuppressive TME, assessing its predictive power for immunotherapy response, and examining its association with various mutational landscapes.